Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2003008637 - UTILISATION DU GENOTYPAGE DANS L'INDIVIDUALISATION DES THERAPIES

Considéré comme nul:  22.10.2003
Numéro de publication WO/2003/008637
Date de publication 30.01.2003
N° de la demande internationale PCT/CA2002/001103
Date du dépôt international 17.07.2002
Demande présentée en vertu du Chapitre 2 10.02.2003
CIB
C12Q 1/68 2006.01
CCHIMIE; MÉTALLURGIE
12BIOCHIMIE; BIÈRE; SPIRITUEUX; VIN; VINAIGRE; MICROBIOLOGIE; ENZYMOLOGIE; TECHNIQUES DE MUTATION OU DE GÉNÉTIQUE
QPROCÉDÉS DE MESURE OU DE TEST FAISANT INTERVENIR DES ENZYMES, DES ACIDES NUCLÉIQUES OU DES MICRO-ORGANISMES; COMPOSITIONS OU PAPIERS RÉACTIFS À CET EFFET; PROCÉDÉS POUR PRÉPARER CES COMPOSITIONS; PROCÉDÉS DE COMMANDE SENSIBLES AUX CONDITIONS DU MILIEU DANS LES PROCÉDÉS MICROBIOLOGIQUES OU ENZYMOLOGIQUES
1Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
68faisant intervenir des acides nucléiques
CPC
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/106
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
C12Q 2600/172
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
172Haplotypes
Y02A 90/22
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
90Technologies having an indirect contribution to adaptation to climate change
10Information and communication technologies [ICT] supporting adaptation to climate change.
20specially adapted for the handling or processing of medical or healthcare data, relating to climate change
22for administrative, organizational or management aspects influenced by climate change adaptation
Y02A 90/26
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
90Technologies having an indirect contribution to adaptation to climate change
10Information and communication technologies [ICT] supporting adaptation to climate change.
20specially adapted for the handling or processing of medical or healthcare data, relating to climate change
26for diagnosis or treatment, for medical simulation or for handling medical devices
Déposants
  • XANTHUS LIFE SCIENCES, INC. [US/US]; 141 Portland Street Cambridge, MA 02139, US (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NE, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW)
  • LEYLAND-JONES, Brian [CA/US]; US (UsOnly)
Inventeurs
  • LEYLAND-JONES, Brian; US
Mandataires
  • OGILVY RENAULT ; Suite 1600 1981 McGill College Avenue Montreal, Québec H3A 2Y3, CA
Données relatives à la priorité
60/305,63017.07.2001US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) USE OF GENOTYPING IN THE INDIVIDUALIZATION OF THERAPY
(FR) UTILISATION DU GENOTYPAGE DANS L'INDIVIDUALISATION DES THERAPIES
Abrégé
(EN)
The invention relates to the individualization of therapy. More specifically, the present invention relates to the use of genotyping for the individualization of therapy and/or individualization of drug dosing. More specifically, the present invention relates to the use of genotyping in the individualization of therapy with a therapeutic agent or a class of therapeutic agents.
(FR)
La présente invention concerne l'individualisation de thérapies. En particulier, l'invention concerne l'utilisation du génotypage dans l'individualisation de thérapies et/ou l'individualisation de posologies. En particulier, l'invention se rapporte à l'utilisation du génotypage dans l'individualisation des thérapies faisant appel à un agent thérapeutique ou à une classe d'agents thérapeutiques.
Également publié en tant que
Dernières données bibliographiques dont dispose le Bureau international